192 related articles for article (PubMed ID: 16279588)
21. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study.
Pierce B; Richardson CL; Lacloche L; Allen A; Ison MG
Transpl Infect Dis; 2018 Apr; 20(2):e12852. PubMed ID: 29380479
[TBL] [Abstract][Full Text] [Related]
23. Ganciclovir and Foscarnet Therapy of Cytomegalovirus-Associated Meningoencephalitis in a Hemodialysis Patient With Liver Transplantation: Case Report.
Kang GW; Hong HL; Lee IH; Ahn KS; Kim JD; Choi DL
Transplant Proc; 2016 May; 48(4):1208-11. PubMed ID: 27320588
[TBL] [Abstract][Full Text] [Related]
24. Panresistant cytomegalovirus in a kidney transplant recipient.
Yost SE; Echeverria A; Jie T; Kaplan B
Pharmacotherapy; 2014 Jan; 34(1):e1-3. PubMed ID: 24277702
[TBL] [Abstract][Full Text] [Related]
25. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.
Isada CM; Yen-Lieberman B; Lurain NS; Schilz R; Kohn D; Longworth DL; Taege AJ; Mossad SB; Maurer J; Flechner SM; Mawhorter SD; Braun W; Gordon SM; Schmitt SK; Goldman M; Long J; Haug M; Avery RK
Transpl Infect Dis; 2002 Dec; 4(4):189-94. PubMed ID: 12535261
[TBL] [Abstract][Full Text] [Related]
27. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients.
Limaye AP
Semin Respir Infect; 2002 Dec; 17(4):265-73. PubMed ID: 12497543
[TBL] [Abstract][Full Text] [Related]
28. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
29. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
[TBL] [Abstract][Full Text] [Related]
30. Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: A case report and literature review.
Morita S; Shinoda K; Tamaki S; Kono H; Asanuma H; Nakagawa K; Oya M
J Clin Virol; 2016 Sep; 82():133-138. PubMed ID: 27494108
[TBL] [Abstract][Full Text] [Related]
31. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
[TBL] [Abstract][Full Text] [Related]
32. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.
Beam E; Lesnick T; Kremers W; Kennedy CC; Razonable RR
Clin Transplant; 2016 Mar; 30(3):270-8. PubMed ID: 26701733
[TBL] [Abstract][Full Text] [Related]
34. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
35. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.
Limaye AP; Raghu G; Koelle DM; Ferrenberg J; Huang ML; Boeckh M
J Infect Dis; 2002 Jan; 185(1):20-7. PubMed ID: 11756977
[TBL] [Abstract][Full Text] [Related]
36. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients.
Ozaki KS; Câmara NO; Nogueira E; Pereira MG; Granato C; Melaragno C; Camargo LF; Pacheco-Silva A
Clin Transplant; 2007; 21(5):675-80. PubMed ID: 17845644
[TBL] [Abstract][Full Text] [Related]
37. CMV resistance: "more complicated than we thought".
Mascolini M
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):37-9. PubMed ID: 11363529
[TBL] [Abstract][Full Text] [Related]
38. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
[TBL] [Abstract][Full Text] [Related]
39. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
40. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
